Italia markets closed

Valneva SE (VLA.PA)

Paris - Paris Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
9,72-0,18 (-1,84%)
Alla chiusura: 05:35PM CEST
Schermo intero
Chiusura precedente9,91
Aperto9,95
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno9,65 - 10,08
Intervallo di 52 settimane7,26 - 29,70
Volume549.245
Media Volume778.499
Capitalizzazione1,14B
Beta (5 anni mensile)0,93
Rapporto PE (ttm)N/D
EPS (ttm)-0,71
Prossima data utili10 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A14,46
  • GlobeNewswire

    Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate

    Saint-Herblain (France), August 18, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that it has initiated rolling submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of the Company’s single-shot chikungunya vaccine candidate in persons aged 18 years and above. This BLA submission follows final pivotal Phase 3 data reported in March 20221 and final lot-to-lot consistency results r

  • GlobeNewswire

    Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense

    Saint Herblain (France), August 18, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that the U.S. Department of Defense (DoD) has decided not to exercise the second option year of the contract1 to supply Valneva’s Japanese encephalitis (JE) vaccine IXIARO®. Due to the past and ongoing impact of the COVID-19 pandemic on its operations, the DoD considers its existing IXIARO® supply levels sufficient to meet current needs. The DoD has communicated

  • GlobeNewswire

    Valneva Establishes an At-the-Market (ATM) Program on Nasdaq

    Saint-Herblain (France), August 15, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) relating to an At-the-Market offering (the “ATM Program”). Pursuant to this new financing program, the Company may offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $75.0 million of American Depositar